Premaitha Health receives CQC accreditation

Premaitha Health receives CQC accreditation

Premaitha Health Plc receives CQC accreditation for new NIPT clinical service laboratory to support IONA® test customers.

Seneca EIS Portfolio company Premaitha, the developer of the IONA® test, the first CE-marked non-invasive prenatal screening test (NIPT), has received Care Quality Commission (CQC) accreditation for its new NIPT service laboratory. The CQC is an independent regulator of health and social care in England. Its accreditation enables Premaitha to provide the IONA® test as a service in-house to support its customers.

The clinical laboratory service is based on Manchester Science Park, adjacent to Premaitha’s headquarters. Its function is to allow new customers to provide pregnant women with access to the IONA® test as soon as possible, whilst their own lab is being established. Premaitha will offer an interim screening facility to which blood samples can be sent.

Dr Stephen Little, CEO of Premaitha said: “We want to be able to offer a clinical laboratory service to support customers keen to provide the IONA® test at the earliest possible opportunity. The accreditation validates the quality of our facilities and the expertise of our clinical scientists. Together, with our partners, we can bring the benefits of NIPT to more pregnant women, sooner.”

See the article in full at Premaitha.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.